Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed Childhood Standard-Risk B-Cell ALL of Average or High Risk of Relapse By Ogkologos - January 13, 2025 931 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COG AALL1731 study Source RELATED ARTICLESMORE FROM AUTHOR Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for Patients with Metastatic Hormone-Sensitive Prostate Cancer Metastatic Breast Cancer: ESMO Living Guideline EMA Recommends Extension of Indications for Datopotamab Deruxtecan MOST POPULAR Implementation of Molecular Tumour Board Portal Developed Under the Umbrella of... May 25, 2022 Liquid Biopsy May Predict Risk of Breast Cancer Returning Years Later August 15, 2018 FDA Approves Capivasertib with Abiraterone and Prednisone for PTEN-deficient Androgen Pathway... July 15, 2026 Coronavirus and cancer – July updates July 7, 2020 Load more HOT NEWS Study Aims to Reduce Lung Cancer Stigma by Teaching Health Professionals... Fruquintinib Prolongs Survival Compared with Placebo in Heavily Pretreated Patients with... Pembrolizumab May Help Prevent Early-Stage Melanoma from Returning Some Hormone Therapy Drugs For Breast Cancer Could Reduce Alzheimer’s Risk
